The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.
作者信息
Meduri G Umberto, Chrousos George P, Arabi Yaseen M
机构信息
Memphis Veterans Affairs Medical Center Research Service and Pulmonary, Critical Care, and Sleep Medicine Service, Memphis, TN, USA.
Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
出版信息
Intensive Care Med. 2021 Mar;47(3):357-358. doi: 10.1007/s00134-020-06335-5. Epub 2021 Jan 28.
Abstract
摘要
相似文献
1
The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.
Intensive Care Med. 2021 Mar;47(3):357-358. doi: 10.1007/s00134-020-06335-5. Epub 2021 Jan 28.
2
Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.
Intensive Care Med. 2021 Mar;47(3):355-356. doi: 10.1007/s00134-020-06330-w. Epub 2021 Jan 2.
3
The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.
Intensive Care Med. 2020 Nov;46(11):2067-2070. doi: 10.1007/s00134-020-06223-y. Epub 2020 Oct 7.
4
Reply to "A limitation regarding the association between intranasal corticosteroid use and better COVID-19 outcomes: Nasal symptoms matter".
J Allergy Clin Immunol Pract. 2022 Jan;10(1):355-356. doi: 10.1016/j.jaip.2021.10.062.
5
Short-term Outcomes of Corticosteroid Monotherapy in COVID-19-Associated Multisystem Inflammatory Syndrome in Children-Handle With Caution-Reply.
JAMA Pediatr. 2022 Sep 1;176(9):946-947. doi: 10.1001/jamapediatrics.2022.2322.
6
Corticosteroid administration for viral pneumonia: COVID-19 and beyond.
Clin Microbiol Infect. 2020 Sep;26(9):1171-1177. doi: 10.1016/j.cmi.2020.06.020. Epub 2020 Jun 27.
7
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Lancet. 2024 Apr 6;403(10434):1339. doi: 10.1016/S0140-6736(23)02881-7.
8
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Lancet. 2024 Apr 6;403(10434):1338-1339. doi: 10.1016/S0140-6736(23)02884-2.
9
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Lancet. 2024 Apr 6;403(10434):1338. doi: 10.1016/S0140-6736(23)02883-0.
10
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
Lancet. 2024 Apr 6;403(10434):1337. doi: 10.1016/S0140-6736(23)02880-5.
本文引用的文献
1
Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.
Intensive Care Med. 2021 Mar;47(3):355-356. doi: 10.1007/s00134-020-06330-w. Epub 2021 Jan 2.
2
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS.
Intensive Care Med. 2020 Dec;46(12):2284-2296. doi: 10.1007/s00134-020-06289-8. Epub 2020 Nov 4.
3
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.
Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa421. doi: 10.1093/ofid/ofaa421. eCollection 2020 Oct.
4
General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections.
Front Endocrinol (Lausanne). 2020 Apr 22;11:161. doi: 10.3389/fendo.2020.00161. eCollection 2020.
5
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
Lancet Respir Med. 2020 Mar;8(3):267-276. doi: 10.1016/S2213-2600(19)30417-5. Epub 2020 Feb 7.
Zotero 插件